IDEXX Laboratories (IDXX) · Life Sciences
IDEXX Laboratories Q2 2026 earnings: summary, key numbers & outlook
Results filed 4 Aug 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
IDEXX's inVue Dx installed base passed 9,000 instruments as Catalyst, Fecal Dx and inVue Dx innovation drove deeper customer adoption and higher diagnostic testing utilization.
IDEXX's growth this quarter came from testing volume and net new customers rather than price alone. Management credits its Catalyst, Fecal Dx and IDEXX inVue Dx platforms for deeper adoption and higher diagnostic utilization. The inVue Dx installed base passed 9,000 instruments after over 1,600 placements. Premium instrument installed base grew 11% globally, which supports consumables demand. Veterinary software was helped by cloud-native growth, and diagnostic imaging had another record quarter of installations, led by ImageVue DR50 Plus.
Management is steering toward what it calls durable, compounding growth under its Technology for Life strategy. It is raising its outlook while continuing incremental investment in commercial capabilities and innovation, including IDEXX Cancer Dx panel expansion and Fine Needle Aspiration on inVue Dx. The tension is that instrument sales are falling against a strong launch comparison, and rapid assay volume is being displaced by the new Catalyst Pancreatic Lipase Test. A stronger U.S. dollar also trims reported revenue guidance.
Key numbers
- Revenue · GAAP
- $1,217 million
- Net income attributable to stockholders · GAAP
- $338.4M
- Diluted EPS · GAAP
- $4.27
- Gross margin · GAAP
- 64.0%
- Operating profit · GAAP
- $425.6M
- Operating margin · GAAP
- 35.0%
- Net cash provided by operating activities · GAAP
- $347.2M
- Free cash flow · non-GAAP
- $322.5M
up 10% as reported and 9% organic
up 18% as reported and 15% on a comparable basis
up 140 basis points as reported and 120 basis points on a comparable basis
up 14% as reported
up 140 basis points as reported and 110 basis points on a comparable basis
| Segment or metric | Value | Change |
|---|---|---|
| CAG Diagnostics recurring revenue | $974.7M | up 11.0% as reported, 10.3% organic |
| IDEXX inVue Dx placements in the quarter | over 1,600 | installed base surpasses 9,000 instruments |
| IDEXX VetLab consumables | 430.3M | up 14.7% as reported, 13.6% organic |
| Reference laboratory diagnostic and consulting services | 406.7M | up 10.6% as reported, 10.3% organic |
| Rapid assay products | 101.6M | up 1.3% as reported, 1.1% organic |
| CAG Diagnostics capital instruments | $47.2M | down 19.5% as reported, 19.6% organic |
| Veterinary software, services and diagnostic imaging systems | $96.3M | up 12.2% as reported, 11.8% organic |
| Water | $58.6M | up 14.8% as reported, 13.0% organic |
Where each number comes from
- Revenue: “The Company reports revenues of $1,217 million for the second quarter of 2026, an increase of 10% as reported and 9% organic”
- Net income attributable to stockholders: “Provision for income taxes | 78,812 | 68,363 | 155,808 | 135,770 Net Income: | Net income attributable to stockholders | $338,412 | $293,989 | $616,858 | $536,666”
- Diluted EPS: “Second quarter earnings per diluted share (“EPS”) were $4.27, an increase of 18% as reported and 15% on a comparable basis.”
- Gross margin: “Gross margin of 64.0% increased 140 basis points as reported and 120 basis points on a comparable basis, supported by strong recurring revenue volume gains”
- Operating profit: “Operating profit and growth (as reported) | $425,566 | $373,046 | 14% | $788,152 | $689,580 | 14%”
- Operating margin: “Operating margin was 35.0% for the quarter, higher than the prior year period by 140 basis points as reported and by 110 basis points on a comparable basis.”
- Net cash provided by operating activities: “Net cash provided by operating activities | $347,162 | $185,743 | $613,410 | $423,705”
- Free cash flow: “Investing cash flows attributable to purchases of property and equipment | (24,646) | (34,102) | (56,630) | (64,128) Free cash flow1 | $322,516 | $151,641”
- CAG Diagnostics recurring revenue: “CAG Diagnostics recurring revenue: | $974,713 | $877,995 | $96,718 | 11.0% | 0.7% | — | 10.3%”
- IDEXX inVue Dx placements in the quarter: “IDEXX inVue Dx™ installed base surpasses 9,000 instruments, supported by over 1,600 placements during the quarter.”
- IDEXX VetLab consumables: “IDEXX VetLab consumables | 430,337 | 375,112 | 55,225 | 14.7% | 1.1% | — | 13.6%”
- Reference laboratory diagnostic and consulting services: “Reference laboratory diagnostic and consulting services | 406,729 | 367,694 | 39,035 | 10.6% | 0.3% | — | 10.3%”
- Rapid assay products: “Rapid assay products | 101,575 | 100,240 | 1,335 | 1.3% | 0.3% | — | 1.1%”
- CAG Diagnostics capital instruments: “CAG Diagnostics capital – instruments | $47,174 | $58,600 | ($ | 11,426) | (19.5 | %) | 0.1% | — | (19.6 | %)”
- Veterinary software, services and diagnostic imaging systems: “Veterinary software, services and diagnostic imaging systems: | $96,349 | $85,848 | $10,501 | 12.2% | 0.4% | — | 11.8%”
- Water: “Water | $58,564 | $51,001 | $7,563 | 14.8% | 1.9% | — | 13.0%”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $1.2B | +9.7% | +6.6% |
| Operating income | $425.6M | +14.1% | +17.4% |
| Net income | $338.4M | +15.1% | +21.5% |
| Diluted EPS | $4.27 | +17.6% | +23.1% |
| Free cash flow | $322.5M | +112.7% | +37.7% |
| Gross margin | 64.0% | +1.4 pts | +0.6 pts |
| Operating margin | 35.0% | +1.4 pts | +3.2 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Revenue | full year 2026 | $4,700 million - $4,745 million |
| Organic revenue growth | full year 2026 | 8.5% - 9.7% |
| CAG Diagnostics recurring revenue organic growth | full year 2026 | 9.5% - 10.7% |
| Reported operating margin | full year 2026 | 32.3% - 32.5% |
| EPS | full year 2026 | $14.69 - $14.94 |
| Capital expenditures | full year 2026 | approximately $180 million |
| Effective tax rate | full year 2026 | ~ 21.1% |
Key takeaways
inVue Dx installed base passed 9,000 instruments
IDEXX placed over 1,600 inVue Dx analyzers in the quarter, widening the base for recurring consumables. Capital instrument revenue still fell 19% as reported because the prior-year period included the broad availability launch.
Premium installed base expansion is feeding consumables
The global premium instrument installed base grew 11%, and VetLab consumables grew 15% as reported with testing utilization gains and recent product launches. This shows the placement-then-consumables model working.
New testing is shifting volume within rapid assays
Rapid assay revenue rose only 1%, with the Catalyst Pancreatic Lipase Test shifting some testing across modalities. Management says the volume impact is easing.
Software and imaging added to the platform story
Veterinary software, services and diagnostic imaging revenue grew 12%, helped by cloud-native software growth and installed base expansion. Imaging had another record quarter of installations, led by ImageVue DR50 Plus.
Investment continues in commercial reach and innovation
Operating expense growth funded commercial capabilities, the innovation agenda and IT investments. Pipeline items named include IDEXX Cancer Dx panel expansion and Fine Needle Aspiration on inVue Dx, with an Investor Day on August 13, 2026.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $954.3M * |
| Q1 2025 | $998.4M |
| Q2 2025 | $1.1B |
| Q3 2025 | $1.1B |
| Q4 2025 | $1.1B * |
| Q1 2026 | $1.1B |
| Q2 2026 | $1.2B |
| Q3 2026 | $1.2B |
Data
| Q1 2025 | $2.96 |
| Q2 2025 | $3.63 |
| Q3 2025 | $3.40 |
| Q1 2026 | $3.47 |
| Q2 2026 | $4.27 |
| Q3 2026 | $4.01 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 27.4% |
| Q1 2025 | 31.7% |
| Q2 2025 | 33.6% |
| Q3 2025 | 32.1% |
| Q4 2025 | 28.9% |
| Q1 2026 | 31.8% |
| Q2 2026 | 35.0% |
| Q3 2026 | 33.1% |
Data
| Q4 2024 | $232.8M |
| Q1 2025 | $207.9M |
| Q2 2025 | $151.6M |
| Q3 2025 | $371.2M |
| Q4 2025 | $326.3M |
| Q1 2026 | $234.3M |
| Q2 2026 | $322.5M |
| Q3 2026 | $420.8M |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What drove IDEXX's growth this quarter?
CAG Diagnostics recurring revenue grew on strong volume, net customer expansion, IDEXX innovation and growth of the premium instrument installed base. Management cites Catalyst, Fecal Dx and inVue Dx as supporting deeper adoption and higher utilization.
How is the IDEXX inVue Dx rollout going?
The installed base now exceeds 9,000 instruments, with over 1,600 placements in the quarter. Fine Needle Aspiration is slated for rollout to the analyzer.
Why did capital instrument revenue fall?
It declined 19% as reported because it was lapping the Q2 2025 broad availability of inVue Dx, though the current period still benefited from over 1,600 placements.
How did IDEXX's international business compare with the U.S.?
CAG Diagnostics recurring revenue grew 14% reported and 12% organic internationally, versus 10% reported and organic in the U.S. Management says U.S. growth outpaced sector growth levels.
How did IDEXX change its 2026 outlook?
It narrowed revenue guidance to $4,700 million - $4,745 million, raised the organic growth range to 8.5% - 9.7%, and lifted EPS guidance to $14.69 - $14.94. A stronger U.S. dollar took $15 million off projected revenue.
Documents
SEC filing